CompletedNot Applicable

The Role of CD34 + Stem Cells and Biomarkers in the Development of CAV in HTX Patients

Slovenia55 participantsStarted 2022-06-01

Plain-language summary

Coronary allograft vasculopathy represents one of the major limiting factors of long-term survival in heart transplant recipients. While extensively researched, the underlying mechanisms of coronary allograft vasculopathy (CAV) after heart transplantation remain incompletely understood. As CD34+ cells represent one of the key determinants of coronary vascular homeostasis we investigated the potential association between CAV and CD34+ cell count in heart transplant recipients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * heart transplant recipient * age \> 18 years * signed informed consent Exclusion Criteria: * multiorgan transplantation * eGFR \< 30 ml/min * known hypersensitivity to the contrast media * history of any malignancy treated with radiation or chemotherapy * therapy with mTOR inhibitors * rejection \> 1R within 90 days before enrollment * G-CSF therapy within 30 days of enrollment

What they're measuring

CD34+ peripheral cell count in heart transplant recipients with and without coronary allograft vasculopathy

Timeframe: at the time of enrollment

Trial details

NCT IDNCT05485467

SponsorUniversity Medical Centre Ljubljana

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-08-15

View on ClinicalTrials.gov More Vasculopathy trials